Baricitinib in moderate to severe rheumatoid arthritis: dose-dependent efficacy and safety in a randomized clinical trial in a developing country
Patients with rheumatoid arthritis (RA) who have an inadequate response or intolerance to methotrexate require effective and safe alternative therapies. Baricitinib, a Janus kinase inhibitor, has shown efficacy in RA, but dose-dependent outcomes in developing countries remain li…